entertainment -WSS

entertainment

author：fashion 2025-10-01 04:33:13 - browse：96

Illustraion of an abstract genome figure made of dots. -- health coverage from STAT — Adobe

LONDON — A decade ago, the U.K. launched its 100,000 Genomes Project, a major research endeavor that involved sequencing the DNA of that many people to discover how our genes shape our health.

But the initiative wasn’t just focused on sequencing our regular DNA. One arm of the project also entailed decoding the genomes of some participants’ tumors.

In a paper published Thursday morning in the U.K., researchers reported their findings from more than 13,800 solid tumors in adults, detailing that certain tumors were more likely to carry mutations that could inform patient care, whether by steering treatment choices or indicating a potential familial risk. The findings are already influencing clinical practice: It’s becoming standard for patients in the National Health Service with those tumors — including types of brain cancers, sarcomas, and ovarian cancers — to get their tumors sequenced.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： The dental labor crisis is a moment of opportunity

entertainment

WSS

PhRMA lawsuit over Medicare drug price negotiation tossed

Medicare threatens to cut off funding for HCA's Mission hospital

'A game

White House Covid adviser calls on docs to combat misinformation

PBMs drew scrutiny in House hearing — and so did pharma

How digital tools helped lower hypertension in marginalized patients

explore

entertainment

hotspot

Medical leaders decry Supreme Court decision on affirmative action

What we’ve learned from the Aduhelm mess

Medicare proposal to cover medical devices draws a mixed reaction

House panel takes first step toward fixing drug shortages

Peter Hotez and the public health issue of online harassment

What we’ve learned from the Aduhelm mess

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

BioAge raises $170M for combination therapy with Zepbound

Drug repurposing or repositioning? The language matters

FDA weighs limits of animal data in assessing artificial wombs

hotspot

White House Covid adviser calls on docs to combat misinformation

Private equity deals in Medicare Advantage declines

To avoid data mishandling cases, universities eye AI and other tools

Biogen Alzheimer’s drug launch off to slow start

The unintended consequences of overturning Roe v. Wade

FDA panel to weigh safety of artificial wombs for preterm births

entertainment

hotspot

entertainment

focus